Literature DB >> 6508360

Estrone sulfatase activity in normal and abnormal endometrium.

G L Adessi, O Prost, G Agnani, A Petitjean, J Burnod.   

Abstract

We investigated the activity of estrone sulfatase in normal and pathological endometrium. In normal endometrium, the estrone sulfatase activity [pmol E1 X min-1 X (mg prot)-1] was 23.13 +/- 8.44 (mean +/- SD). An increase (p less than 0.01) of estrone sulfatase activity (62.81 +/- 21.97) was noted in mild endometrial hyperplasia. In focal hyperplasia (when the measurements were performed in the normal endometrial biopsies) such an increase was not noted (19.10 +/- 5.33). Estrone sulfatase activities of moderate hyperplasia (25.30 +/- 11.40) and endometrial neoplasia (30.30 +/- 9.57) were in the same range as in normal endometrium. Treatment with progestagen simultaneously reduced hyperplasia and estrone sulfatase activity. But when morphologically abnormal endometrium persisted after treatment, estrone sulfatase activity remained increased. The increase of estrone sulfatase activity appeared to be specific to mild endometrial hyperplasia. The role of estrone sulfatase in the pathogenesis of endometrial hyperplasia is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508360     DOI: 10.1007/bf02114864

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  18 in total

1.  Estradiol binding and metabolism in human endometrial hyperplasia and adenocarcinoma.

Authors:  E Gurpide; S B Gusberg; L Tseng
Journal:  J Steroid Biochem       Date:  1976 Nov-Dec       Impact factor: 4.292

2.  Defining the pathology of endometrial hyperplasia, dysplasia and carcinoma.

Authors:  S C Sommers
Journal:  Pathol Res Pract       Date:  1982-08       Impact factor: 3.250

3.  Solubilization and partial purification of steroid sulfatase of human placenta.

Authors:  R Gauthier; N Vigneault; G Bleau; A Chapdelaine; K D Roberts
Journal:  Steroids       Date:  1978-06       Impact factor: 2.668

Review 4.  Extraglandular oestrogen formation and serum binding of oestradiol: relationship to cancer.

Authors:  P K Siiteri
Journal:  J Endocrinol       Date:  1981       Impact factor: 4.286

5.  Studies of the biochemical basis of steroid sulphatase deficiency: preliminary evidence suggesting a defect in membrane-enzyme structure.

Authors:  R W McNaught; J T France
Journal:  J Steroid Biochem       Date:  1980-03       Impact factor: 4.292

6.  Human endometrial cells in primary tissue culture: modulation of the progesterone receptor level by natural and synthetic estrogens in vitro.

Authors:  R L Eckert; B S Katzenellenbogen
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

7.  Induction of estrogen sulfotransferase in the human endometrium by progesterone in organ culture.

Authors:  C L Clarke; J B Adams; B G Wren
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

8.  Properties of steroid sulphatase and arylsulphatase activities of human placenta.

Authors:  A P French; J C Warren
Journal:  Biochem J       Date:  1967-10       Impact factor: 3.857

Review 9.  The cytodynamics of endometrial hyperplasia and carcinoma. A review.

Authors:  A Ferenczy; M M Gelfand; F Tzipris
Journal:  Ann Pathol       Date:  1983-09       Impact factor: 0.407

10.  Stimulation of arylsulfotransferase activity by progestins in human endometrium in vitro.

Authors:  L Tseng; H C Liu
Journal:  J Clin Endocrinol Metab       Date:  1981-08       Impact factor: 5.958

View more
  2 in total

Review 1.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

Review 2.  The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases.

Authors:  Tea Lanišnik Rižner
Journal:  Front Pharmacol       Date:  2016-02-18       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.